ダウンロード数: 511
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s00417-012-2022-8.pdf | 463.08 kB | Adobe PDF | 見る/開く |
タイトル: | Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. |
著者: | Oishi, Akio https://orcid.org/0000-0002-0977-9458 (unconfirmed) Yamashiro, Kenji Tsujikawa, Akitaka Ooto, Sotaro Tamura, Hiroshi https://orcid.org/0000-0002-7740-2732 (unconfirmed) Nakata, Isao Miyake, Masahiro Yoshimura, Nagahisa |
著者名の別形: | 大石, 明生 |
キーワード: | Choroidal neovascularization High myopia Bevacizumab Anti-VEGF therapy Chorioretinal atrophy |
発行日: | Jan-2013 |
出版者: | Springer-Verlag |
誌名: | Graefe's archive for clinical and experimental ophthalmology |
巻: | 251 |
号: | 1 |
開始ページ: | 1 |
終了ページ: | 7 |
抄録: | [Purpose]To investigate the long-term visual prognosis and progression of chorioretinal atrophy in patients with myopic choroidal neovascularization (mCNV) treated with intravitreal injections of bevacizumab. [Methods]Hospital-based, retrospective, cross-sectional study. In total, 22 patients (22 eyes) with treatment-naïve mCNV who underwent intravitreal injection of bevacizumab and were followed up for more than 48 months were investigated. Visual acuity and fundus photographs before and 1, 2, 3, and 4 years after initial treatment in the clinics were compared and judged if chorioretinal atrophy (CRA) developed/enlarged or remained unchanged. The influence of clinical characteristics including age, sex, axial length, baseline visual acuity, CNV area, CNV location, and number of injections were investigated with logistic regression analysis. [Results]Mean logarithm of the minimum angle of resolution (logMAR) improved from 0.76 to 0.52 (P < .01), 0.48 (P < .01), and 0.54 (P < .05) after 1, 2, and 3 years, respectively. The effect slightly declined to marginally non-significant levels after 4 years (logMAR, 0.59; P = .07). CRA developed or enlarged in nine cases (41 %) in 1 year, reaching 16 cases (73 %) at the final visit. Those without CRA enlargement achieved better visual improvement. None of the aforementioned patient characteristics significantly affected CRA. [Conclusions]Anti-VEGF therapy for mCNV is effective for vision improvement in the long term. On the other hand, development or enlargement of CRA frequently occurred, and affected visual improvement. Strategies to manage atrophy should be the next step in achieving better visual outcome upon mCNV treatment. |
著作権等: | The final publication is available at www.springerlink.com This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/169724 |
DOI(出版社版): | 10.1007/s00417-012-2022-8 |
PubMed ID: | 22527326 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。